Redhill Biopharma Ltd (RDHL)

10.32
0.18 1.70
NASDAQ : Health Care
Prev Close 10.50
Open 10.39
Day Low/High 10.23 / 10.69
52 Wk Low/High 8.10 / 17.09
Volume 72.01K
Avg Volume 65.80K
Exchange NASDAQ
Shares Outstanding 17.06M
Market Cap 166.49M
EPS -2.30
P/E Ratio 51.37
Div & Yield N.A. (N.A)

Latest News

RedHill Biopharma Reports 2017 Second Quarter Financial Results

RedHill Biopharma Reports 2017 Second Quarter Financial Results
RedHill Biopharma To Host Second Quarter 2017 Financial Results Conference Call On July 25, 2017

RedHill Biopharma To Host Second Quarter 2017 Financial Results Conference Call On July 25, 2017
RedHill Biopharma Announces Last Patient Visit In BEKINDA® Phase II Study For IBS-D

RedHill Biopharma Announces Last Patient Visit In BEKINDA® Phase II Study For IBS-D

RedHill Biopharma Announces Expected Timeline For DSMB Meeting And Provides Update On Enrollment In The RHB-104 Phase III Study For Crohn's Disease

RedHill Biopharma Announces Expected Timeline For DSMB Meeting And Provides Update On Enrollment In The RHB-104 Phase III Study For Crohn's Disease

RedHill Biopharma To Host Conference Call On Successful Phase III Top-Line Results With BEKINDA® For Acute Gastroenteritis

RedHill Biopharma Announces Confirmatory Phase III Study Initiated With RHB-105 (TALICIA™) For H. Pylori Infection

RedHill Biopharma Announces Successful Phase III Top-Line Results With BEKINDA® For Acute Gastroenteritis

RedHill Biopharma Initiates Promotion Of Donnatal® And EnteraGam® In The U.S.

RedHill Biopharma To Present At The 2017 BIO International Convention

RedHill Biopharma Announces Poster Presentation Of The Positive RHB-105 Phase III Results For H. Pylori Infection At Digestive Disease Week 2017

RedHill Biopharma Reports 2017 First Quarter Financial Results

RedHill Biopharma To Host First Quarter 2017 Financial Results Conference Call On May 3, 2017

RedHill Biopharma Announces Enrollment Of Last Patient In The BEKINDA® Phase II Study For IBS-D

RedHill Biopharma Announces Peer-Reviewed Publication Of The Positive YELIVA® Phase I Study Results In Advanced Solid Tumors

RedHill Biopharma To Host R&D Day On BEKINDA® For Acute Gastroenteritis And IBS-D

RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering BEKINDA®

RedHill Biopharma And IntelGenx Announce Marketing Approval Of RIZAPORT® For Migraines In Luxembourg

RedHill Biopharma Announces Exclusive U.S. License From Entera Health For Commercial GI Product EnteraGam®

RedHill Biopharma Receives FDA Orphan Drug Designation For YELIVA® For The Treatment Of Cholangiocarcinoma

RedHill Biopharma To Present At BioCentury Future Leaders In The Biotech Industry Conference

RedHill Biopharma To Present At The 2017 MAP Conference

RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease

RedHill Biopharma To Present At The BIO-Europe Spring 2017 Conference

RedHill Biopharma's Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating To Donnatal®

3 Small Biotechs That Still Have Upside

3 Small Biotechs That Still Have Upside

Companies developing drugs for cancer, eye problems and pets -- offer untapped value.

RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website

RedHill Biopharma Reports 2016 Fourth Quarter And Full-Year Financial Results

RedHill Biopharma Completes Treatment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis

RedHill Biopharma To Host Fourth Quarter And Full-Year 2016 Financial Results Conference Call On February 23, 2017

RedHill Biopharma Announces Enrollment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis

Load More
Quant Rating on 11:02 AM EDT 7/26/2017

D

(Sell)

From Our Partners

2 Small-Cap Biotechs To Put On Your Radar
SeekingAlpha

Healthcare - Top 5 Gainers / Losers as of 11:00 am
SeekingAlpha

RedHill Bio Q2 loss widens 68%
SeekingAlpha

Redhill beats by $0.52, beats on revenue
SeekingAlpha

3 Things In Biotech You Should Learn Today: July 20, 2017
SeekingAlpha

RedHill updates on Crohn's candidate RHB-104, second DSMB review later this month
SeekingAlpha

Q3 Biotech Catalyst Watch: Phase 3 Data Releases (Part 2)
SeekingAlpha

BEKINDA Phase III GUARD Study Top-Line Results
SeekingAlpha

RedHill Biopharma (RDHL) Presents At BIO International Conference 2017 - Slideshow
SeekingAlpha

RedHill launches late-stage study of H. pylori killer RHB-105; shares down 2% premarket on carryover from yesterday's reversal
SeekingAlpha

RedHill's Bekinda successful in late-stage gastroenteritis study; shares ahead 7% premarket
SeekingAlpha

Premarket Gainers as of 9:05 am
SeekingAlpha

RedHill Bio launches two GI products in U.S., shares up 3%
SeekingAlpha

Biotech Forum Daily Digest: Analysts Warming To Mylan; Spotlight On Seres Therapeutics
SeekingAlpha

Redhill Biopharma: $10 Biotech Stock With Upcoming Catalysts
SeekingAlpha
TheStreet Quant Rating: D (Sell)

Get the (RDHL)
Report Here

Trending
Jim Cramer on Advanced Micro Devices, Boeing, Coca-Cola, Chipotle, McDonald's, Citigroup, Southwest Airlines, Amazon and Starbucks
Corning Takes Damaging Hit on Earnings -- Here's Where Investors Can Buy
Facebook's Q2 Results Should Make Snap CEO Evan Spiegel Wish He Had Accepted a $3B Buyout Offer
10 Things to Buy With What Johnny Depp Spends a Month
Advanced Micro Devices Could Explode Another 17% Within Hours: Chart